DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effectiveness of durvalumab in combination
with standard chemotherapy for mesothelioma. All participants in the study will receive
standard first-line chemotherapy for mesothelioma. Two thirds of the participants in the
study will be randomly assigned to also receive a new treatment called durvalumab. Durvalumab
is an antibody (a type of human protein) that works by blocking a body substance called
Programmed death-ligand 1 (PD-L1).
Blocking PD-L1 helps the body's immune system to attack cancer cells. Research has shown that
durvalumab can slow tumour growth and shrink tumours in some people with cancer. Previous
studies of combining durvalumab and chemotherapy showed that this combination is active in
advanced mesothelioma.
This international study is being led jointly by the University of Sydney in Australia, and
the Pr Eastern Cooperative Oncology Group (PrECOG) in the USA. The study plans to enrol 480
participants from hospitals throughout Australia, New Zealand and the USA.
Phase:
Phase 3
Details
Lead Sponsor:
University of Sydney
Collaborators:
AstraZeneca Australasian Lung Cancer Trials Group PrECOG, LLC.